DCGI approves anti-Covid drug developed by DRDO for emergency use
PTI, May 8, 2021, 3:41 PM IST
New Delhi: The Drugs Controller General of India has approved an anti-COVID oral drug, developed by DRDO, for emergency use as an adjunct therapy in moderate to severe COVID-19 patients, the defence ministry said on Saturday.
It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
The drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories in Hyderabad.
The 2-DG comes in powder form in sachet and is taken orally by dissolving it in water.
”On May 01, DCGI granted permission for emergency use of this drug as an adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country,” the ministry said in a statement.
”It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique,” the ministry said.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
SC asks Centre to respond within 3 weeks to pleas seeking stay of Citizenship (Amendment) Rules, 2024
Cal HC refuses urgent hearing of demolition matters, says “let human lives be saved”
Manipur govt in favour of UPSC exam centres outside state: Delhi HC told
Himachal: BJP delegation meets chief electoral officer, complains of model code of conduct violations
PM Modi’s ‘400 paar’ claim ‘hollow’, INDIA bloc will get clear majority to form govt: Baghel
MUST WATCH
Latest Additions
Unilever is cutting 7,500 jobs and spinning off its ice cream business
Audi to drive in over 20 new models by 2025-end: CEO Gernot Dollner
Piracy sites in India pose greater risk of malware, surpassing adult sites, gambling ads: Study
Cong distributing cookers to lure voters in Bangalore Rural LS segment: JD(S) leader Kumaraswamy
SC asks Centre to respond within 3 weeks to pleas seeking stay of Citizenship (Amendment) Rules, 2024